To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate | MicrobiomeTrials← Back to trialsNCT06488911
To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate
TERMINATEDPHASE3INTERVENTIONAL
Trial Details
Start: 2024-07-01Est. Completion: 2025-10-21
Enrollment target: 62 participants Locations- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Southern California Research Center, Coronado, California, United States
- Tampa General Medical Group, Tampa, Florida, United States
- Piedmont Atlanta Hospital, Atlanta, Georgia, United States
- Ochsner Clinic Foundation, New Orleans, Louisiana, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- NYU Langone Health, New York, New York, United States
- University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
- Gastro One, Germantown, Tennessee, United States
- East Tennessee Research Institute, Johnson City, Tennessee, United States
- The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas, United States
- Houston Methodist Hospital, Houston, Texas, United States
- American Research Corporation, San Antonio, Texas, United States
- DIM Clinica Privada, Buenos Aires, Argentina
- Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
- Hospital Italiano de La Plata, Buenos Aires, Argentina
- Hospital Universitario Austral, Buenos Aires, Argentina
- Hospital Provincial del Centenario, Santa Fe, Argentina
- Royal Adelaide Hospital, Adelaide, Australia
- Flinders Medical Centre, Bedford Park, Australia
- UZ Leuven, Leuven, Belgium
- University of Alberta Division of Gastroenterology Zeidler Ledcor Centre, Edmonton, Alberta, Canada
- Pacific Gastroenterology Associates GI Research Institute, Vancouver, British Columbia, Canada
- Universityl Hospital Dubrava, Zagreb, Croatia
- Hepato-Gastroenterologie HK, s.r.o., Hradec Králové, Czechia
- Artroscan s.r.o. Gastroenterologicka, Ostrava, Czechia
- Research Site SRO, Pilsen, Czechia
Other microbiome trials you might be interested in
Primary Biliary Cholangitis (PBC)
The present phase 1b/2 randomised, double-blind, placebo-controlled, two-part study is designed to evaluate the safety, …
Düsseldorf, GermanyEst. completion Aug 31, 2026
FragilityBiliary ObstructionCholangitisMalignancy
This prospective, randomized, single-center study aims to evaluate and compare two different sedation and analgesia regi…
Ankara, Turkey (Türkiye)Est. completion May 30, 2026
Tartu University Hospital, Tartu, EstoniaHopital Henri Mondor, Créteil, FranceCHRU de Lille, Lille, FranceCHU Paris Est - Hopital Saint Antoine, Paris, FranceHopital de la Pitie Salpetriere, Paris, FranceMedizinische Hochschule Hannover, Hanover, GermanyUniversity Hospital of Larissa, Larissa, GreeceDEOEC II. sz. Belgygyszati Klinika, Debrecen, HungaryHadassah Ein-Karem Medical Center - Liver unit, Jerusalem, IsraelAzienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi, Bologna, ItalyUniversity Hopital Santaros klinikos, Vilnius, LithuaniaAcademisch Medisch Centrum, Amsterdam, NetherlandsAkershus University Hospital, Lørenskog, NorwayKyungpook National University Hospital, Daegu, South KoreaSeoul National University Bundang Hospital, Seongnam-si, South KoreaHospital ClinicUniversity of Barcelona, Barcelona, SpainConsorcio Hospital General Universitario, Valencia, SpainHacettepe University, Faculty of Medicine, Adult Hospital Gastroenterology, Ankara, Turkey (Türkiye)Ege University, Faculty of Medicine, Gastroenterology, Bornova, Turkey (Türkiye)Istanbul University, Capa Faculty of Medicine, Gastroenterology, Istanbul, Turkey (Türkiye)Harran University Hospital, Gastroenterology, Sanliurfa, Turkey (Türkiye)Hull University Teaching Hospitals NHS Trust, Hull, United KingdomInstitute of Cellular Medicine Newcastle University, Newcastle upon Tyne, United KingdomJohn Radcliffe Hospital, Oxford, United KingdomPrimary Sclerosing Cholangitis
Background:
Primary sclerosing cholangitis is a rare chronic liver disease. It affects the bile ducts of the
liver. It…
Bethesda, United StatesEst. completion Oct 31, 2026